Clinical utility of serum cystatin C in predicting coronary artery disease

Cardiology Journal

Volumn 17, Issue 4, 2010, Pages 374-380

  Koc, Mevlut ^a   Batur, Mustafa Kemal ^a   Karaarslan, Osman ^a   Abali, Gülcan ^a  

^a ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Coronary artery disease; Cystatin C; Markers of atherosclerosis

Indexed keywords

C REACTIVE PROTEIN; CREATININE; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CROSS-SECTIONAL STUDIES; CYSTATIN C; FEMALE; HOMOCYSTEINE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TURKEY; UP-REGULATION;

EID: 77954962468     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Shlipak MG, Sarnak MJ, Katz R et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med, 2005; 352: 2049-2060.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004; 351: 1296-1305.
3. Weiner DE, Tighiouart H, Amin MG et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol, 2004; 15: 1307-1315.
4. Weber JA, van Zanten AP. Interferences in current methods for measurements of creatinine. Clin Chem, 1991; 37: 695-700.
5. Coll E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis, 2000; 36: 29-34.
6. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant, 2003; 18: 2024-2031.
7. Laterza OF, Price CP, Scott MG. Cystatin C: An improved estimator of glomerular filtration rate? Clin Chem, 2002; 48: 699-707.
8. Filler G, Bökenkamp A, Hofmann W, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR: History, indications, and future research. Clin Biochem, 2005; 38: 1-8.
9. Arpegård J, Ostergren J, de Faire U, Hansson LO, Svensson P. Cystatin C: A marker of peripheral atherosclerotic disease? Atherosclerosis, 2008; 199: 397-401.
10. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem, 2005; 51: 321-327.
11. Eriksson P, Deguchi H, Samnegård A et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol, 2004; 24: 551-557.
12. Jernberg T, Lindahl B, James S et al. Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation, 2004; 110: 2342-2348.
13. Bassand JP, Hamm CW, Ardissino D et al. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2007; 28: 1598-1660.
14. Luc G, Bard JM, Lesueur C et al.; PRIME Study Group. Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis, 2006; 185: 375-380.
15. Wang J, Sim AS, Wang XL et al. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis, 2008; 197: 853-859.
16. Niccoli G, Conte M, Della Bona R et al. Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis, 2008; 198: 373-380.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron, 1976; 1: 110-114.
18. Gardin JM, Adams DB, Douglas PS et al.; American Society of Echocardiography. Recommendations for a standardized report for adult transthoracic echocardiography: A report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr, 2002; 15: 275-290.
19. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation, 1977; 55: 613-618.
20. Shub C, Klein AL, Zachariah PK, Bailey KR, Tajik AJ. Determination of left ventricular mass by echocardiography in a normal population: Effect of age and sex in addition to body size. Mayo Clin Proc, 1994; 69: 205-211.
21. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983; 51: 606.
22. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med, 2001; 134: 629-636.
23. Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transplant, 2007; 22: 1087-1092.
24. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: A systematic review and meta-analysis. Mayo Clin Proc, 2008; 83: 1203-1212.
25. Bostom AG, Bausserman L, Jacques PF, Liaugaudas G, Selhub J, Rosenberg IH. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Arterioscler Thromb Vasc Biol, 1999; 19: 2241-2244.
26. Bostom AG, Gohh RY, Bausserman L et al. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. J Am Soc Nephrol, 1999; 10: 164-166.